• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Christopher Simon to the Board of Directors

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $HAE alert in real time by email

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.

    For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previously, Mr. Simon served as a Senior Partner of McKinsey & Company, a strategy and management consulting firm, where he led the Global Medical Products Practice. Prior to his career at McKinsey & Company, Mr. Simon served in commercial and operating roles at Baxter Healthcare Corporation, now Baxter International Inc., a healthcare company, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion. He brings more than 30 years of experience in helping businesses transform and grow.



    "We are excited to welcome Chris to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Chris's leadership experience as a public company CEO and his extensive commercial and strategic experience in the life sciences industry will serve as tremendous assets as we continue to grow."

    Mr. Simon also currently serves on the board of directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts 
    Jason Peterson

    Vice President Investor Relations & Treasurer, Sotera Health

    [email protected]
     
      
      
    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    [email protected]
     

    Source: Sotera Health Company



    Primary Logo

    Get the next $HAE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE
    $SHC

    CompanyDatePrice TargetRatingAnalyst
    Sotera Health Company
    $SHC
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    Sotera Health Company
    $SHC
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    Sotera Health Company
    $SHC
    12/18/2025Outperform
    William Blair
    Haemonetics Corporation
    $HAE
    12/15/2025Buy → Hold
    Needham
    Haemonetics Corporation
    $HAE
    12/11/2025$88.00Buy → Neutral
    Citigroup
    Sotera Health Company
    $SHC
    11/13/2025$19.00Outperform
    BMO Capital Markets
    Haemonetics Corporation
    $HAE
    8/11/2025$78.00Strong Buy → Outperform
    Raymond James
    Haemonetics Corporation
    $HAE
    8/8/2025$62.00Overweight → Neutral
    Analyst
    More analyst ratings

    $HAE
    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 25 million shares of its common stock, par value $0.01 per share. All 25 million shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Regist

    3/4/26 4:51:01 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

    BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation. The 510(k) clearance was supported by clinical

    2/23/26 4:15:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kroll Mark W bought $98,784 worth of shares (1,400 units at $70.56), increasing direct ownership by 6% to 24,757 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    11/12/25 4:18:34 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sotera Health upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sotera Health from Neutral to Overweight and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital Mkts resumed coverage on Sotera Health with a new price target

    RBC Capital Mkts resumed coverage of Sotera Health with a rating of Outperform and set a new price target of $24.00

    1/9/26 8:12:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    William Blair initiated coverage on Sotera Health

    William Blair initiated coverage of Sotera Health with a rating of Outperform

    12/18/25 9:11:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Petras Michael B. Jr. covered exercise/tax liability with 190,297 shares, converted options into 89,686 shares and was granted 240,248 shares, increasing direct ownership by 25% to 692,427 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    3/4/26 9:17:59 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SVP, General Counsel and Sec. Dimitrief Alexander covered exercise/tax liability with 31,560 shares and converted options into 16,816 shares, decreasing direct ownership by 4% to 319,981 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    3/4/26 8:55:56 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 38,274 shares, converted options into 17,937 shares and was granted 59,355 shares, increasing direct ownership by 21% to 228,620 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    3/4/26 8:54:25 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    SEC Filings

    View All

    SEC Form 424B7 filed by Sotera Health Company

    424B7 - Sotera Health Co (0001822479) (Filer)

    3/5/26 4:11:20 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 424B7 filed by Sotera Health Company

    424B7 - Sotera Health Co (0001822479) (Filer)

    3/4/26 5:20:13 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    3/3/26 6:09:10 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $HAE
    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date

    CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2025 before the market opens on Tuesday, February 24, 2026. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's websit

    2/17/26 7:30:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registra

    2/5/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care